ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
Militia Long/Short Equity ETF
31.64
+0.1188
0.38%
盤後:
31.63
-0.0088
-0.03%
16:04 EDT
成交量:
10.81萬
成交額:
342.65萬
市值:
1.38億
市盈率:
- -
高:
31.85
開:
31.74
低:
31.61
收:
31.52
52周最高:
32.87
52周最低:
25.63
股本:
436.00萬
流通股本:
431.00萬
量比:
2.38
換手率:
2.51%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞
安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據
格隆汇
·
10/21
FAK賽道處於爆發前夜!應世生物深耕佈局,全球領跑
蓝鲸财经
·
10/14
藥明巨諾:國產病毒載體版倍諾達補充申請獲國家藥監局受理
财中社
·
10/09
創新藥尋突圍,「自研+引入」雙軌戰略能否重塑增長極?
21世纪经济报道
·
09/26
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":31.6388,"timestamp":1761249600000,"preClose":31.52,"halted":0,"volume":108136,"hourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.6388,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"delay":0,"floatShares":4310000,"shares":4360000,"eps":0,"marketStatus":"盤後交易","change":0.1188,"latestTime":"10-23 18:32:10 EDT","open":31.74,"high":31.8485,"low":31.61,"amount":3426477.35722,"amplitude":0.007567,"askPrice":47.47,"askSize":200,"bidPrice":31,"bidSize":80,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1761264000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":31.52,"sharesOutstanding":4360000,"nav":31.26,"aum":136293600,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.63,"preClose":31.6388,"latestTime":"16:04 EDT","volume":1,"amount":31.63,"timestamp":1761249851524},"volumeRatio":2.382994},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4310000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.382994,"shares":4360000,"dividePrice":0,"high":31.8485,"amplitude":0.007567,"preClose":31.52,"low":31.61,"week52Low":25.63,"pbRate":"--","week52High":32.87,"institutionHeld":0,"latestPrice":31.6388,"committee":-0.428571,"eps":0,"divideRate":0,"volume":108136,"delay":0,"ttmEps":0,"open":31.74,"prevYearClose":25.88,"prevWeekClose":31.18,"prevMonthClose":31.475,"prevQuarterClose":31.475,"fiveDayClose":30.9996,"twentyDayClose":32.0026,"sixtyDayClose":29.9947},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577639389","title":"安科生物披露創新藥HuA21注射液在2025年歐洲腫瘤內科學會年會公佈臨牀研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2577639389","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577639389?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 08:53","pubTimestamp":1761007995,"startTime":"0","endTime":"0","summary":"格隆汇10月21日丨安科生物公布,公司于2025年10 月 17 日至 21 日在德国柏林召开的欧洲肿瘤内科学会年会上,以壁报形式公布自主研发的生物创新药重组抗 HER2 人源化HuA21 单克隆抗体注射液联合曲妥珠单抗和化疗治疗HER2 阳性晚期胃/胃食管交界处腺癌 Ib/II 期剂量递增和扩展研究的最新研究成果。HuA21 通过诱导 HER2 受体的内吞和下调,打断癌细胞信号通路,从而抑制癌细胞生长和增殖,产生促进癌细胞凋亡、抗肿瘤血管生成等效果,最终达到抑制肿瘤的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021085601a6c4ac4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","BK4181","PK","KG","BK4218","BK4019"],"gpt_icon":0},{"id":"2575701254","title":"FAK賽道處於爆發前夜!應世生物深耕佈局,全球領跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2575701254","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575701254?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 12:29","pubTimestamp":1760416190,"startTime":"0","endTime":"0","summary":"协同管线布局,拓展治疗边界为巩固赛道领先地位,应世生物还布局了第二代选择性FAK抑制剂IN10028,依托ifebemtinib的研发经验,优化与RAS抑制剂、ADC等疗法的协同效果,计划于2025年第四季度提交IND申请,2026年启动首次人体临床试验。Ifebemtinib有望成为同类最佳的选择性FAK抑制剂,凭借ifebemtinib的先发优势与协同管线布局,应世生物有望在这一蓝海市场中占据领先地位。截至2025年3月末,公司账上的现金及","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760316553550547598","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4563","BK4509","BK4171","BK4108","BK4007","TME","BK4224","BK4585","LU0456842615.SGD","LU2039709279.SGD","BK4588","BK4565","IE00BYQNZ168.SGD","PLD","BK4535","PROC","BK4526","LU0359201612.USD","BK4531","BK4548","BK4534","IE00B12V2V27.USD","LU0359202008.SGD","IE00BYTNYN87.SGD","ORR","01698","SG9999011746.SGD","BK4552","BK4571","BK4567","LU1023057109.AUD"],"gpt_icon":0},{"id":"2574538681","title":"藥明巨諾:國產病毒載體版倍諾達補充申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2574538681","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574538681?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 17:48","pubTimestamp":1760003334,"startTime":"0","endTime":"0","summary":"10月9日,药明巨诺(02126)发布公告,中国国家药品监督管理局已正式受理公司倍诺达?使用国产病毒载体的上市后补充申请。此次申请基于一项II期单臂研究,旨在评估使用新工艺病毒载体(JWLV011)生产的瑞基奥仑赛注射液与现有病毒载体生产的产品可比性。研究结果显示,3个月最佳客观缓解率(ORR)为66.67%,疾病完全缓解率(CR)为41.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510093529591131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4161","CR","ORR"],"gpt_icon":0},{"id":"2570035010","title":"創新藥尋突圍,「自研+引入」雙軌戰略能否重塑增長極?","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035010","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570035010?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 12:59","pubTimestamp":1758862756,"startTime":"0","endTime":"0","summary":"与此同时,2025年第二季度中国创新药对外BD首付款金额高达17.3亿美元,远超同期中国生物医药投融资金额6.9亿美元。根据药智网公布的数据,创新药从临床试验Ⅰ期到批准上市的可能性为12.69%,而整体研发成功率则更低。BD合作已成为创新药研发投入的新资金来源和主要资金来源。柳丹指出,未盈利创新药企需多元融资保障生存。今年上半年全球医药交易TOP10中,中国创新药资产的贡献率超过80%,且交易金额最高的资产也来自国内药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LEGN","BK4505","BK4588","ORR","BK4585","BK4139","02142"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}